Welcome to our dedicated page for CalciMedica SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. (CALC) approved and is implementing a 1-for-5 reverse stock split of its outstanding common stock and a reduction of authorized common shares from 500,000,000 to 100,000,000 through a Certificate of Amendment filed in Delaware.
The amendment becomes effective at 5:00 p.m. Eastern Time on August 28, 2026. Every five issued and outstanding common shares will be combined into one share, with no change in par value. Equity awards, warrants and plan reserves will be adjusted proportionately, and holders otherwise entitled to fractional shares will receive cash instead. CALC shares will begin trading on a split-adjusted basis on August 31, 2026 on The Nasdaq Capital Market under the same ticker.
CalciMedica, Inc. (CALC) has a significant shareholder group led by Stonepine Capital Management, LLC reporting ownership on a Schedule 13G. Stonepine Capital Management, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico together report beneficial ownership of 2,149,522 CalciMedica common stock equivalents, representing 6.0% of the outstanding common stock.
The position consists of 643,357 shares of common stock and warrants to acquire an additional 1,506,165 shares, all subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 34,141,460 shares of common stock outstanding as of August 5, 2026. Voting and dispositive powers over these securities are reported as shared among the Stonepine entities and Plexico, with no sole voting or dispositive power.
CalciMedica, Inc. (CALC) reported that major stockholder ALAFI CAPITAL CO LLC acquired two new warrant positions on August 19, 2026. The holder received 3,529,192 Series A Warrants exercisable into the same number of common shares at $0.8033 per share and 3,529,192 Series B Warrants at an exercise price of $1.00 per share. The Series A Warrants expire on the earlier of 18 months after the closing date of a related private placement or 30 days following CalciMedica’s public announcement of FDA clearance of its Investigational New Drug Application for CM5480, while the Series B Warrants expire on June 23, 2031. After these transactions, ALAFI CAPITAL CO LLC directly holds 5,112,345 shares of CalciMedica common stock.
CalciMedica, Inc. (CALC) received an updated Schedule 13D from Alafi Capital Company LLC and Christopher D. Alafi reporting their beneficial ownership of 7,220,101 shares of common stock and related warrants, representing 19.9% of the class based on 34,141,460 shares outstanding as of August 20, 2026.
The position includes 5,112,345 common shares plus multiple warrant series. On August 19, 2026, after Stockholder Approval, the reporting persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants. Due to a 19.99% beneficial ownership limitation, 2,605,965 Series A Warrants and 2,605,965 Series B Warrants are not currently exercisable. The filing states the amendment’s purpose is solely to reflect this warrant issuance, with no stated change in transaction purpose.
CalciMedica, Inc. (CALC) reported that director Allan Shaw received a grant of 10,000 Director Stock Options to purchase common stock. The options have an exercise price of $0.6131 per share and expire on August 18, 2036. According to the vesting terms, 1/12 of the shares vest in equal monthly installments over one year following the grant date, and the award will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders. Following this grant, Shaw holds 10,000 options directly.
CalciMedica, Inc. (CALC) reported that director Alan Glicklich received a grant of 10,000 Director Stock Options to purchase Common Stock at an exercise price of $0.6131 per share. The options expire on August 18, 2036 and are scheduled to vest monthly over one year, and in any event be fully vested by the 2027 annual meeting of stockholders.
CalciMedica, Inc. (CALC) reported that director Frederic Guerard received a grant of 10,000 Director Stock Options on 2026-08-19. Each option allows purchase of one share of common stock at an exercise price of $0.6131 per share and expires on 2036-08-18. According to the vesting terms, 1/12th of the options vest in equal monthly installments over one year following the grant date, and the options will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders. Following this grant, Guerard holds 10,000 derivative securities directly.
CalciMedica, Inc. (CALC) reported that director Evgeny Zaytsev, through Bering Partners II, L.P., was granted two series of warrants, each covering 1,450,267 shares of common stock, with exercise prices of $0.8033 and $1.00 per share, respectively. Both warrants become exercisable on or after August 19, 2026 and are subject to a 9.99% beneficial ownership cap. In addition, Zaytsev received a directly held director stock option for 10,000 shares at an exercise price of $0.6131 per share, vesting in monthly installments over one year and expiring on August 18, 2036.
CalciMedica, Inc. (CALC) reported that director Robert N. Wilson received derivative awards on August 19, 2026. He was granted two warrants for 1,182,621 shares each of common stock, with exercise prices of $0.8033 and $1.00 per share, acquired under a Securities Purchase Agreement approved by an independent board committee. These warrants are exercisable starting August 19, 2026, subject to a 19.99% beneficial ownership limitation and specified expiration dates tied to December 25, 2027 or 30 days after public disclosure of FDA clearance of CM5480, and June 25, 2031, respectively. Wilson also received a stock option for 10,000 shares at an exercise price of $0.6131 per share, vesting in 12 equal monthly installments over one year and in any event fully vesting by the 2027 annual meeting of stockholders.
CalciMedica, Inc. (CALC) reported that Chief Medical Officer Sudarshan Hebbar received two warrant awards linked to a Securities Purchase Agreement dated June 23, 2026, with a June 25, 2026 closing, approved by an independent board committee. Each warrant covers 124,486 shares of Common Stock, one with a $0.8033 per-share exercise price expiring as early as December 25, 2027 and the other with a $1.00 exercise price expiring on June 25, 2031. Both become exercisable on or after August 19, 2026 and are subject to a beneficial ownership cap not exceeding 19.99%.